SEC Form 4 · accession 0002009762-26-000006

Harmony Biosciences Holdings, Inc. · HRMY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Kumar Budur

Officer — CHIEF MEDICAL OFFICER

Period of report

Sep 16, 2026

Accepted (ET)

Sep 18, 2026 · 4:48 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001802665

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Sep 16, 2026	M	900	$30.69	A	14,015	D
Common Stock	Sep 16, 2026	M	900	$30.27	A	14,915	D
Common Stock^F2	Sep 16, 2026	S	1,800	$43.0146	D	13,115	D
Common Stock	Sep 17, 2026	M	400	$30.69	A	13,515	D
Common Stock	Sep 17, 2026	M	400	$30.27	A	13,915	D
Common Stock	Sep 17, 2026	S	800	$43.00	D	13,115	D
Common Stock	Sep 18, 2026	M	10,406	$30.69	A	23,521	D
Common Stock	Sep 18, 2026	M	25,446	$30.27	A	48,967	D
Common Stock^F3	Sep 18, 2026	S	35,852	$43.0545	D	13,115	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option^F4	$30.69	Sep 16, 2026	M	900	D	—	Jan 24, 2034	Common Stock	900	29,400	D
Stock Option^F5	$30.27	Sep 16, 2026	M	900	D	—	May 1, 2034	Common Stock	900	63,346	D
Stock Option^F4	$30.69	Sep 17, 2026	M	400	D	—	Jan 24, 2034	Common Stock	400	29,000	D
Stock Option^F5	$30.27	Sep 17, 2026	M	400	D	—	May 1, 2034	Common Stock	400	62,946	D
Stock Option^F4	$30.69	Sep 18, 2026	M	10,406	D	—	Jan 24, 2034	Common Stock	10,406	18,594	D
Stock Option^F5	$30.27	Sep 18, 2026	M	25,446	D	—	May 1, 2034	Common Stock	25,446	37,500	D

Explanation of responses

F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.03. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
F5The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.